Neurocrine Biosciences (NBIX) Cost of Revenue (2017 - 2026)

Neurocrine Biosciences has reported Cost of Revenue for 10 years, with the latest figure at $13.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 50.0% year-over-year to $13.8 million; the trailing twelve-month figure through Mar 2026 stood at $56.7 million (up 58.82% YoY), and the FY2025 full-year result was $52.1 million, up 53.24% from the prior year.
• Cost of Revenue for Q1 2026 stood at $13.8 million, down from $17.6 million in the prior quarter.
• The five-year high for Cost of Revenue was $17.6 million in Q4 2025, with the low at $4.6 million in Q1 2022.
• Historically, Cost of Revenue has averaged $9.6 million across 5 years, with a median of $9.2 million in 2024.
• Annual changes were most pronounced in 2023 — Cost of Revenue soared 139.58% — and 2024, when it dropped 28.57%.
• Neurocrine Biosciences' Cost of Revenue stood at $7.7 million in 2022, then increased by 10.39% to $8.5 million in 2023, then rose by 9.41% to $9.3 million in 2024, then jumped by 89.25% to $17.6 million in 2025, then declined by 21.59% to $13.8 million in 2026.
• The last three Cost of Revenue figures came in at $13.8 million (Q1 2026), $17.6 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.